Nieuws
19
IMI launches call fifteen and sixteen
The JTI Innovative Medicines Initiative 2 (IMI JU) has launched its fifteenth and sixteenth call for proposals. The indicative budget available for the 15th call with identifier H2020-JTI-IMI2-2018-15-TWO-STAGE is € 386,722,862. The Stage 1 submission deadline is October 24, 2018. The indicative budget available for the 16th call with identifier H2020-JTI-IMI2-2018-16-SINGLE-STAGE is € 46,900,000. The submission deadline is October 24, 2018.
Call fifteen includes eight topics:
- Topic 1: Integrated research platforms enabling patient-centric drug development
- Topic 2: Blockchain Enabled Healthcare
- Topic 3: Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases
- Topic 4: Emerging translational safety technologies and tools for interrogating human immuno-biology
- Topic 5: Development and validation of translational platforms in support of synaptopathy drug discovery
- Topic 6: Digital endpoints in neurodegenerative and immune-mediated diseases
Topics under the IMI2 Antimicrobial Resistance (AMR) Accelerator programme
- Topic 7: AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries
- Topic 8: AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic
Call sixteen includes seven topics:
- Topic 1: Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for tuberculosis (TB) that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
- Topic 2: Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
- Topic 3: Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomarkers for TB and NTM infection
- Topic 4: Determination of gepotidacin levels in tonsils and prostatic tissue
- Topic 5: Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections
- Topic 6: Functional Ethionamide boosters: a novel combination for tuberculosis therapy
- Topic 7: Intravenous treatments of serious infections (urinary tract infections (UTI), intra-abdominal infections (IAI) & hospital-acquired pneumonia/ventilator associated pneumonia (HAP/VAP)) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)
The goal of the IMI2 is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI. Like IMI, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe's pharmaceutical industry.
Terug naar overzichtContactgegevens
InnoFunding B.V.
Nieuwe Gracht 7
2011 NB Haarlem
Mail: info@innofunding.nl